On March 24, 2023, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that the patent applications for their independently developed products, IMM47 (CD24 antibody), IMM2520 (CD47×PD-L1), and IMM2510 (VEGF×PD-L1), have been approved by the China National Intellectual Property Administration. The approval of these patents in China will significantly enhance the market competitiveness of these projects and represent another milestone achievement in ImmuneOnco's rapid development.

CD24 is widely expressed in various solid tumors, including breast cancer, non-small cell lung cancer, colorectal cancer (CRC), hepatocellular carcinoma, renal cell carcinoma (RCC), and ovarian cancer (OC), and is considered an important prognostic marker for poor outcomes in these cancers, demonstrating significant potential for clinical research. The CD24 monoclonal antibody IMM47 is in the pre-IND stage and is expected to submit an IND application to the National Medical Products Administration and the US Food and Drug Administration this year.

IMM2520 has been approved by the China NMPA and the US FDA for clinical trials, and patent approvals are also underway in countries/regions such as the United States and Europe. Preclinical toxicity studies of IMM2520 have shown that it does not bind to human red blood cells. In various animal models, IMM2520 has demonstrated encouraging efficacy and safety. The first participant in the IMM2520 project was dosed on March 23, 2023.

Preliminary results from the phase I clinical trial of the IMM2510 project have shown effectiveness. As of February 15, 2023, in patients with advanced solid tumors, good safety and tolerability have been demonstrated at doses up to 10.0mg/kg of IMM2510. Two partial responses have been observed in two evaluable non-small cell lung cancer patients, with best tumor shrinkage rates of 46% and 35%, respectively.

Founder and Chairman of ImmuneOnco Biopharmaceuticals

Dr. Wenzhi Tian stated:

"We are delighted to have received approval from the National Intellectual Property Administration of China for the invention patents of all three of our projects: IMM47, IMM2520, and IMM2510. We believe that these three projects have significant clinical development value. We will actively promote clinical trials and research, and strive to bring these projects to market as soon as possible to benefit cancer patients."